# Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer

> **NCT00171587** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 22 (estimated)

## Conditions studied

- Tumors
- Neoplasm Metastasis

## Interventions

- **DRUG:** PTK787/ZK 222584 (vatalanib)

## Key facts

- **NCT ID:** NCT00171587
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2009-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171587, "Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00171587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*